New trial aims to shrink colorectal tumors before surgery with targeted drugs
NCT ID NCT05845450
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving a short course of targeted drugs before surgery can improve outcomes for people with colorectal cancer that can be removed. About 197 participants will receive a treatment matched to their tumor's genetic makeup, followed by standard surgery. The goal is to see if this approach leads to fewer or no cancer cells remaining after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
RECRUITINGMilan, Lombardia/MI, 20133, Italy
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?